lung cancer

Closing of the C financing round of our mandate 4D Lifetec AG.

Our portfolio company 4D Lifetec AG is finishing the year strongly. We are happy to share that 4D Lifetec AG has successfully closed a CHF 2 million round of C-financing, securing early clinical validation and the next development phase towards market entry in 2021 in Europe. To finance the expansion of the activities towards a market entry into the US market and extend the clinical trial to US clinics the next capital increase round has already started. Congratulations to the team of 4D Lifetec.